Orphalan Expands Phase 3 Wilson Disease Trial to China

17 November 2026 | Tuesday | News


First participant globally randomised in the TRADITiONAL study, which compares investigational once-daily trientine tetrahydrochloride with D-penicillamine as first-line treatment over 48 weeks.

  • Phase 3 trial evaluates the safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine as first-line treatment in Wilson disease.

  • First participant globally randomised in China at The Second Affiliated Hospital of Zhejiang University School of Medicine, following activation of three leading clinical centres with Beijing Friendship Hospital serving as coordinating lead site.

Orphalan SA  announced the expansion of the TRADITiONAL Study into China, marking the formal randomisation of the first participant into the study globally. TRADITiONAL is an international, multicentre Phase 3 clinical trial evaluating an investigational once-daily formulation of trientine tetrahydrochloride for the first-line treatment of Wilson disease. The study evaluates the safety and efficacy of once-daily trientine tetrahydrochloride compared with D-penicillamine (DPA), an established copper-chelating therapy, over 48 weeks post randomisation.

The global study launched initially in the United States in August 2026 with a progressive activation of sites across the US and the King Faisal Specialist Hospital, Riyadh, Saudi Arabia. Additional sites expected to join this year as global enrolment expands to Pakistan.

This important milestone in China represents the first international study expansion in Wilson disease, with the study's first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. Patient recruitment is now actively open across three leading Chinese hospital institutions, with Beijing Friendship Hospital serving as the coordinating lead site:

  • Beijing Friendship Hospital, Capital Medical University (lead site)
  • The Second Affiliated Hospital, Zhejiang University School of Medicine (site of the first randomised participant)
  • Beijing You'an Hospital, Capital Medical University (activated clinical study site)

"The activation of centres in China and the randomisation of our first participant represent a significant milestone in our goal to develop innovative products addressing the current treatment burden of people living with Wilson disease. Our investigational once-daily formulation will be compared with D-penicillamine as a first-line therapy. Current treatment approaches can be complex for people living with Wilson disease. Our goal is to address the unmet patient needs by investigating options that may provide better support for the daily therapeutic management of Wilson disease while maintaining effective copper control." - Omar Kamlin, Chief Medical Officer, Orphalan

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close